Latest On Zealand Pharma A/S (ZEAL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-11-10 10:48 EST | News | Zealand Pharma reports nine-month results | N/A |  |
| 2022-10-05 01:47 EST | News | Zealand Pharma announces private placement of 4.5M new shares | N/A | |
| 2022-09-30 11:48 EST | News | Zealand says short bowel syndrome therapy reached main goal in Phase 3 trial | N/A | |
| 2022-09-07 12:16 EST | News | Novo Nordisk to pay DKK25M upfront to Zealand Pharma in license deal for Zegalogue | N/A | |
| 2022-08-24 14:58 EST | News | Zealand Pharma appoints CFO | N/A | |
| 2022-08-09 15:58 EST | News | Zealand Pharma to delist U.S.-listed shares, consolidate trading to Nasdaq Copenhagen | N/A | |
| 2022-06-21 20:38 EST | News | Zealand Pharma, Iktos team up to develop AI tech for peptide drug design | N/A | |
| 2022-05-19 14:40 EST | News | Zealand Pharma stock soars 17% as dasiglucagon meets main goal in congenital hyperinsulinism study in infants | N/A | |
| 2022-05-12 10:06 EST | News | Zealand Pharma GAAP EPS of -DKK5.16 misses by $4.18, revenue of DKK15.07M beats by DKK5.59M | N/A | |
| 2022-05-10 20:32 EST | News | Zealand Pharma, Oberland Capital amend financing contract | N/A | |
| 2022-03-30 12:27 EST | News | Zealand Pharma stock rises 10% on restructuring plan, new CEO | N/A | |
| 2022-01-20 14:05 EST | News | Zealand Pharma completes enrollment in phase 3 glepaglutide study for short bowel syndrome | N/A | |
| 2021-12-15 03:33 EST | News | Zealand Pharma inks 7-year, $200M financing deal with Oberland Capital | N/A | |
| 2021-11-22 16:24 EST | News | Zealand Pharma reports successful outcome of Phase 1b trial with dapiglutide | N/A | |
| 2021-11-05 18:55 EST | News | Zealand Pharma and DEKA Research ink collaboration agreement | N/A | |
| 2021-11-04 22:34 EST | News | Zealand Pharma gets dosing underway in Phase 1 ZP8396 obesity trial | N/A | |
| 2021-10-12 18:17 EST | News | Warning: ZEAL is at high risk of performing badly | N/A | |
| 2021-10-07 01:25 EST | News | ZEAL is at high risk of performing badly | N/A | |
| 2021-10-05 22:53 EST | News | Warning: ZEAL has been downgraded to Very Bearish | N/A | |
| 2021-08-20 17:20 EST | News | Zealand Pharma raises share capital after employees exercise warrants | N/A | |
| 2021-08-19 20:23 EST | News | Dosing underway in Zealand Pharma's late-stage glepaglutide study in short bowel syndrome | N/A | |
| 2021-07-22 15:33 EST | News | Boehringer Ingelheim and Zealand Pharma get FDA fast track status for NASH treatment | N/A | |
| 2021-07-22 15:32 EST | News | Zealand Pharma increases share capital led by employee warrants exercise | N/A | |
| 2021-07-22 15:30 EST | News | Zealand Pharma starting share buyback program for employee incentives program | N/A | |
| 2021-04-14 01:27 EST | News | Boehringer Ingelheim, Zealand Pharma initiate mid-stage NASH and obesity studies | N/A | |
| 2021-03-23 16:53 EST | News | Zealand Pharma surges on news of FDA approval for dasiglucagon (updated) | N/A | |
| 2021-03-22 20:17 EST | News | Zealand Pharma surges on news of FDA approval for dasiglucagon | N/A | |
| 2021-03-20 09:01 EST | News | Seeking Alpha Catalyst Watch | N/A | |
| 2021-03-18 07:19 EST | Analyst Rating | The Analyst Target Price has decreased from $39.67 to $39.59. | Neutral | |
| 2021-03-17 15:18 EST | Analyst Rating | The Analyst Target Price has decreased from $39.76 to $39.67. | Neutral | |
| 2021-03-16 23:47 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-16 23:47 EST | Earnings Estimate | An EPS average of -$0.98 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-16 23:47 EST | Earnings Estimate | An EPS average of -$0.99 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2021-03-16 23:47 EST | Analyst Rating | The Analyst Target Price has increased from $38.67 to $39.76. | Buy | |
| 2021-03-13 05:48 EST | Analyst Rating | The Analyst Target Price has increased from $38.48 to $38.67. | Buy | |
| 2021-03-12 06:10 EST | Analyst Rating | The Analyst Target Price has increased from $38.45 to $38.48. | Buy | |
| 2021-03-12 06:10 EST | Earnings Estimate | An EPS average of -$3.20 is estimated for the 2022 year. | Sell | |
| 2021-03-11 20:35 EST | News | Zealand Pharma misses on revenue | N/A | |
| 2021-03-11 05:52 EST | Analyst Rating | The Analyst Target Price has increased from $38.29 to $38.45. | Buy | |
| 2021-03-10 06:27 EST | Analyst Rating | The Analyst Target Price has decreased from $38.55 to $38.29. | Neutral | |
| 2021-03-09 05:58 EST | Analyst Rating | The Analyst Target Price has decreased from $38.67 to $38.55. | Neutral | |
| 2021-03-06 02:07 EST | Analyst Rating | The Analyst Target Price has decreased from $38.94 to $38.67. | Neutral | |
| 2021-03-05 17:41 EST | Analyst Rating | The Analyst Target Price has increased from $38.6 to $38.94. | Buy | |
| 2021-03-05 09:53 EST | Analyst Rating | The Analyst Target Price has decreased from $38.73 to $38.6. | Neutral | |
| 2021-03-04 05:54 EST | Analyst Rating | The Analyst Target Price has increased from $38.61 to $38.73. | Buy | |
| 2021-03-03 09:58 EST | Analyst Rating | The Analyst Target Price has decreased from $38.74 to $38.61. | Neutral | |
| 2021-03-02 17:42 EST | Analyst Rating | The Analyst Target Price has decreased from $38.97 to $38.74. | Neutral | |
| 2021-02-27 05:49 EST | Analyst Rating | The Analyst Target Price has decreased from $38.99 to $38.97. | Neutral | |
| 2021-02-26 22:21 EST | Analyst Rating | The Analyst Target Price has decreased from $39.42 to $38.99. | Neutral | |
| 2021-02-26 06:05 EST | Analyst Rating | The Analyst Target Price has increased from $39.36 to $39.42. | Buy | |
About Zealand Pharma A/S (ZEAL):
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
General
- Name Zealand Pharma A/S
- Symbol ZEAL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 329
- Fiscal Year EndDecember
- IPO Date2017-08-09
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.zealandpharma.com
View More
Valuation
- Trailing PE 10.13
- Price/Sales (Trailing 12 Mt.) 20.68
- Price/Book (Most Recent Quarter) 7.01
- Enterprise Value Revenue 3.26
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$4.20
- Next Year EPS Estimate -$3.64
- Profit Margin -240%
- Return on Assets -30%
- Return on Equity -69%
- Earnings Per Share $3.00
- Revenue Per Share $0
- Gross Profit 262.75 million
- Quarterly Earnings Growth 451.3%
View More
Highlights
- Market Capitalization 1.31 billion
- Analyst Target Price $39.59
- Book Value Per Share $6.32
View More
Share Statistics
- Shares Outstanding 43.34 million
- Shares Float 30.68 million
- % Held by Insiders 1%
- % Held by Institutions 4.24%
- Shares Short 154865
- Shares Short Prior Month 104811
- Short Ratio 7.4
View More
Technicals
- Beta 0.94
- 52 Week High $44.42
- 52 Week Low $26.82
- 50 Day Moving Average 32.58
- 200 Day Moving Average 36.11
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Zealand Pharma A/S (ZEAL) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Zealand Pharma A/S (ZEAL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-11 | $N/A | -$1.56 | -$0.97 | -61.54% |
| 2020-09-30 | 2020-11-12 | $N/A | -$0.91 | -$0.89 | -3.1% |
| 2020-06-30 | 2020-08-13 | $N/A | -$0.25 | -$0.42 | 40.61% |
| 2020-03-31 | 2020-05-14 | $12.42 million | -$0.72 | -$0.66 | -8.89% |
| 2019-12-31 | 2020-03-11 | $11.49 million | -$0.81 | -$0.37 | -121.17% |
| 2019-09-30 | 2019-11-14 | $9.92 million | -$0.51 | -$0.51 | -0.16% |
| 2019-06-30 | 2019-08-15 | $19.92 million | -$0.65 | -$0.67 | 4.17% |
| 2019-03-31 | 2019-05-16 | $N/A | -$0.62 | -$0.60 | -2.33% |
| 2018-12-31 | 2019-03-07 | $7298.89 | -$0.59 | -$0.73 | 18.41% |
| 2018-09-30 | 2018-11-15 | $N/A | $4.56 | $5.19 | -12.05% |
| 2018-06-30 | 2018-08-16 | $2.36 million | -$0.66 | ||
| 2018-03-31 | 2018-05-16 | $1.61 million | -$0.49 | ||
| 2017-12-31 | 2018-03-07 | $2.17 million | -$0.61 | -$0.50 | -22.38% |
| 2017-09-30 | 2017-11-08 | $6.66 million | -$0.23 | -$0.37 | 36.87% |
| 2017-06-30 | 2017-08-24 | $2.27 million | -$0.55 |
Zealand Pharma A/S (ZEAL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Zealand Pharma A/S (ZEAL) Chart:
Zealand Pharma A/S (ZEAL) News:
Below you will find a list of latest news for Zealand Pharma A/S (ZEAL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Zealand Pharma A/S (ZEAL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Zealand Pharma A/S (ZEAL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920078682/0001104659-20-078682-index.htm |
| 2019-09-26 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1674988/000000000019014017/0000000000-19-014017-index.htm |
| 2020-01-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1674988/000090221920000257/0000902219-20-000257-index.htm |
| 2020-03-13 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1674988/000104746920001482/0001047469-20-001482-index.htm |
| 2019-09-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919049859/0001104659-19-049859-index.htm |
| 2019-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919050190/0001104659-19-050190-index.htm |
| 2019-09-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1674988/000110465919050343/0001104659-19-050343-index.htm |
| 2019-09-18 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1674988/000110465919050574/0001104659-19-050574-index.htm |
| 2019-09-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919051194/0001104659-19-051194-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919052016/0001104659-19-052016-index.htm |
| 2019-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919055677/0001104659-19-055677-index.htm |
| 2019-11-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919064697/0001104659-19-064697-index.htm |
| 2019-11-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919067209/0001104659-19-067209-index.htm |
| 2019-11-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919068535/0001104659-19-068535-index.htm |
| 2019-12-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919068748/0001104659-19-068748-index.htm |
| 2019-12-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919070802/0001104659-19-070802-index.htm |
| 2019-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919071754/0001104659-19-071754-index.htm |
| 2019-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919071755/0001104659-19-071755-index.htm |
| 2019-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919071840/0001104659-19-071840-index.htm |
| 2019-12-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919073076/0001104659-19-073076-index.htm |
| 2019-12-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919073081/0001104659-19-073081-index.htm |
| 2019-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465919077178/0001104659-19-077178-index.htm |
| 2020-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920013175/0001104659-20-013175-index.htm |
| 2020-02-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920016274/0001104659-20-016274-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1674988/000110465920021862/0001104659-20-021862-index.htm |
| 2020-03-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920032785/0001104659-20-032785-index.htm |
| 2020-03-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920032787/0001104659-20-032787-index.htm |
| 2020-03-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920033195/0001104659-20-033195-index.htm |
| 2020-03-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920037288/0001104659-20-037288-index.htm |
| 2020-03-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920037290/0001104659-20-037290-index.htm |
| 2020-03-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920037292/0001104659-20-037292-index.htm |
| 2020-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920039089/0001104659-20-039089-index.htm |
| 2020-03-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920040176/0001104659-20-040176-index.htm |
| 2020-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920042381/0001104659-20-042381-index.htm |
| 2020-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920042382/0001104659-20-042382-index.htm |
| 2020-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920042384/0001104659-20-042384-index.htm |
| 2020-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920042399/0001104659-20-042399-index.htm |
| 2020-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920042400/0001104659-20-042400-index.htm |
| 2020-04-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920043932/0001104659-20-043932-index.htm |
| 2020-04-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920043947/0001104659-20-043947-index.htm |
| 2020-04-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920044725/0001104659-20-044725-index.htm |
| 2020-04-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920049313/0001104659-20-049313-index.htm |
| 2020-05-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920054918/0001104659-20-054918-index.htm |
| 2020-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920062754/0001104659-20-062754-index.htm |
| 2020-05-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920065421/0001104659-20-065421-index.htm |
| 2020-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920065833/0001104659-20-065833-index.htm |
| 2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920066353/0001104659-20-066353-index.htm |
| 2020-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920067754/0001104659-20-067754-index.htm |
| 2020-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920067756/0001104659-20-067756-index.htm |
| 2020-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920073440/0001104659-20-073440-index.htm |
| 2020-06-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920073526/0001104659-20-073526-index.htm |
| 2020-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920074545/0001104659-20-074545-index.htm |
| 2020-06-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920075630/0001104659-20-075630-index.htm |
| 2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920076717/0001104659-20-076717-index.htm |
| 2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920076724/0001104659-20-076724-index.htm |
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920078682/0001104659-20-078682-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920081037/0001104659-20-081037-index.htm |
| 2020-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920094974/0001104659-20-094974-index.htm |
| 2020-08-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920098189/0001104659-20-098189-index.htm |
| 2020-09-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920101582/0001104659-20-101582-index.htm |
| 2020-09-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920102756/0001104659-20-102756-index.htm |
| 2020-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920105436/0001104659-20-105436-index.htm |
| 2020-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920105440/0001104659-20-105440-index.htm |
| 2020-09-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920107232/0001104659-20-107232-index.htm |
| 2020-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1674988/000110465920110117/0001104659-20-110117-index.htm |
| 2020-06-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1674988/999999999720003737/9999999997-20-003737-index.htm |